secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neumora Therapeutics, Inc. (NMRA)
CIK:        0001885522
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001193125-26-130372
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neumora FY2025 net loss $236.9M; NMRA-511 positive data; NMRA-215 delayed to Q1 2027; cash to Q3 2027
--------------------------------------------------------------------------------

- Cash $182.5M; FY net loss $236.9M; R&D $176.1M, G&A $60.1M; cash runway into Q3 2027.
- NMRA-511: pre-specified analysis (NPI-AA≥4) shows Cohen's d 0.34 on CMAI total, 0.51 on CMAI aggression.
- Navacaprant: KOASTAL-2 and -3 fully enrolled (>400 each); topline readout expected Q2 2026.
- M4 franchise: NMRA-898 lead; Phase 1 shows ~80-100h half-life, target engagement; MAD study data H2 2026.
- NMRA-215: 12-week DIO data supports switch/maintenance; tox finding in 5/142 rats; clinical now Q1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1885522/000119312526130372/0001193125-26-130372-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1885522/000119312526130372/nmra-20260330.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-130372

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer